Literature DB >> 28181125

Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure.

Matteo Beltrami1, Gaetano Ruocco1, Aladino Ibrahim1, Barbara Lucani1, Beatrice Franci1, Ranuccio Nuti1, Alberto Palazzuoli2,3.   

Abstract

The exact relationship existing among congestion status, brain natriuretic peptide (BNP) changes and acute kidney injury (AKI) has not been elucidated in patients with acute heart failure (AHF). The aims of this study are: to investigate the relation and prognostic role of BNP, AKI and clinical congestion after discharge; to define the exact BNP cut off value or a BNP in-hospital reduction to identify patients with higher risk during vulnerable post-discharge phase. We consecutively enrolled 157 patients with a diagnosis of AHF. BNP and creatinine were measured in all patients, and degree of failure was assessed. AKI was defined as a creatinine increase ≥0.3 mg/dL or eGFR reduction ≥20% during hospitalization. All patients were followed for 1 and 3 months. Of 146 included patients, 110 patients (75%) displayed effective decongestion, 116 (79%) showed a BNP decrease ≥30%, and 28 (19%) developed in-hospital AKI. BNP in-hospital decrease ≥30% was found more often in patients who showed good decongestion in comparison to patients in persistent failure (63 vs 22%; p < 0.001). The ROC curve analyses at 3 months show that both BNP reduction of 30% between admission and discharge and decongestion at discharge identifies patients with a reduced incidence of cardiovascular events (AUC = 0.79, confidence interval 0.68-0.90, sensibility 90%, sensitivity 50% p < 0.001). Kaplan-Meier survival plots show a better outcome in patients with a BNP decrease ≥30% and good decongestion at discharge (p = 0.03). BNP reduction in AHF is associated with decongestion. BNP reduction associated with decongestion at discharge is a favorable prognostic indicator at 90-day survival irrespective of the AKI occurrence.

Entities:  

Keywords:  Acute kidney injury; B-type natriuretic peptide; Clinical congestion; Heart failure; Outcome

Mesh:

Substances:

Year:  2017        PMID: 28181125     DOI: 10.1007/s11739-017-1620-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  38 in total

1.  Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function.

Authors:  Marco Metra; Beth Davison; Luca Bettari; Hengrui Sun; Christopher Edwards; Valentina Lazzarini; Barbara Piovanelli; Valentina Carubelli; Silvia Bugatti; Carlo Lombardi; Gad Cotter; Livio Dei Cas
Journal:  Circ Heart Fail       Date:  2011-12-13       Impact factor: 8.790

2.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.

Authors:  Daniel E Forman; Javed Butler; Yongfei Wang; William T Abraham; Christopher M O'Connor; Stephen S Gottlieb; Evan Loh; Barry M Massie; Michael W Rich; Lynne Warner Stevenson; James B Young; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

3.  Acute heart failure syndromes: current state and framework for future research.

Authors:  Mihai Gheorghiade; Faiez Zannad; George Sopko; Liviu Klein; Ileana L Piña; Marvin A Konstam; Barry M Massie; Edmond Roland; Shari Targum; Sean P Collins; Gerasimos Filippatos; Luigi Tavazzi
Journal:  Circulation       Date:  2005-12-20       Impact factor: 29.690

4.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).

Authors:  Anuradha Lala; Steven E McNulty; Robert J Mentz; Shannon M Dunlay; Justin M Vader; Omar F AbouEzzeddine; Adam D DeVore; Prateeti Khazanie; Margaret M Redfield; Steven R Goldsmith; Bradley A Bart; Kevin J Anstrom; G Michael Felker; Adrian F Hernandez; Lynne W Stevenson
Journal:  Circ Heart Fail       Date:  2015-06-03       Impact factor: 8.790

5.  Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure.

Authors:  Gaspare Parrinello; Salvatore Paterna; Pietro Di Pasquale; Daniele Torres; Manuela Mezzero; Mauro Cardillo; Sergio Fasullo; Gabriella La Rocca; Giuseppe Licata
Journal:  J Card Fail       Date:  2010-12-24       Impact factor: 5.712

6.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.

Authors:  A M Richards; R Doughty; M G Nicholls; S MacMahon; N Sharpe; J Murphy; E A Espiner; C Frampton; T G Yandle
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

7.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.

Authors:  Andrew P Ambrosy; Peter S Pang; Sadiya Khan; Marvin A Konstam; Gregg C Fonarow; Brian Traver; Aldo P Maggioni; Thomas Cook; Karl Swedberg; John C Burnett; Liliana Grinfeld; James E Udelson; Faiez Zannad; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2013-01-04       Impact factor: 29.983

Review 8.  Use of natriuretic peptides to guide and monitor heart failure therapy.

Authors:  A Mark Richards; Richard W Troughton
Journal:  Clin Chem       Date:  2011-11-15       Impact factor: 8.327

9.  Worsening renal function is not associated with response to treatment in acute heart failure.

Authors:  Sameer Ather; Chirag Bavishi; Mark D McCauley; Amandeep Dhaliwal; Anita Deswal; Sarah Johnson; Wenyaw Chan; David Aguilar; Allison M Pritchett; Kumudha Ramasubbu; Xander H T Wehrens; Biykem Bozkurt
Journal:  Int J Cardiol       Date:  2012-05-25       Impact factor: 4.164

10.  Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.

Authors:  Stephen J Greene; Aldo P Maggioni; Gregg C Fonarow; Scott D Solomon; Michael Böhm; Albert Kandra; Margaret F Prescott; Bernard Reimund; Tsushung A Hua; Anastasia Lesogor; Faiez Zannad; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2015-01       Impact factor: 15.534

View more
  4 in total

Review 1.  Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment.

Authors:  Eva M Boorsma; Jozine M Ter Maaten; Kevin Damman; Wilfried Dinh; Finn Gustafsson; Steven Goldsmith; Daniel Burkhoff; Faiez Zannad; James E Udelson; Adriaan A Voors
Journal:  Nat Rev Cardiol       Date:  2020-05-15       Impact factor: 32.419

2.  Copeptin level in the early prediction of cardiorenal syndrome in rats.

Authors:  Xiaosheng Sheng; Li Lin; Fangming Guo; Shuxia Liang; Haohao Chen; Yuanshu Fang; Mingxing Ding
Journal:  Exp Ther Med       Date:  2018-05-30       Impact factor: 2.447

3.  Prognostic value of perioperative NT-proBNP after corrective surgery for pediatric congenital heart defects.

Authors:  Fangqin Lin; Lingling Zheng; Yanqin Cui; Weidan Chen; Ramit Kumar Gupta; Huixian Li; Xinxin Chen; Huimin Xia; Huiying Liang
Journal:  BMC Pediatr       Date:  2019-12-16       Impact factor: 2.125

Review 4.  The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines.

Authors:  Matteo Beltrami; Massimo Milli; Lorenzo Lupo Dei; Alberto Palazzuoli
Journal:  J Clin Med       Date:  2022-04-17       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.